Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

Diaz, N.; Agüero, Fernando; Sued, Omar; Arribas, José Ramón; Ambrosioni, Juan; Blanco, José Luis Santiago; Mora, Lorena de la; García-Alcaide, Felipe; González-Cordón, Ana; Inciarte, Alexis; Laguno, Montserrat; Leal, Lorna; Martínez-Chamorro, Esteban; Martı́nez-Rebollar, Marı́a; Miró, José M.; Rojas, Jhon; Torres, Berta; Mallolas, Josép; Albiac, Laia; Agüero, Daiana; Bodro, Marta; Cardozo, Celia; Chumbita, Mariana; García, Nicol; García-Vidal, Carolina; Hernández‐Meneses, Marta; Herrera, Sabina; Linares, Laura; Moreno, Antonio; Morata, Laura; Martı́nez-Martı́nez, José A.; Puerta, Pedro; Rico, Verónica; Soriano, Álex; Martínez, Mikel J; Mosquera, Marı́a del Mar; Marcos, María Ángeles; Vilà, Jordi; Tuset, Montse; Soy, Dolors; Vilella, Anna; Almuedo, Alex; Pinazo, María Jesús; Muñóz, José

doi:10.1007/s40121-021-00547-y

Cited by 6 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the above mentioned studies, the numbers of PWH participating in clinical trials that evaluated COVID-19 vaccines is still very limited. 39 Weaker neutralization antibody responses to Spike protein were demonstrated in this study, similar to the protein-based vaccine, NVX-CoV2373, studied in South Africa, 36 and the inactivated SARS-CoV-2 vaccine studied in China. 37 CD4 + T cells orchestrate the response to acute and chronic viral infections by coordinating the immune system.…”

Section: Discussionsupporting

confidence: 64%

“…Recent researches have reported PWH with CD4 + T cell counts less than 200 cells/mm 3 presented weaker immunologic responses. [35][36][37][38][39] Second, our study was initiated when SARS-CoV-2 was not endemic in Taiwan, and the low viral transmission rate made it di cult to ascertain the e cacy of the vaccine as an exploratory endpoint. Speci cally, low levels of 1% of neutralizing antibody titer were detected both at baseline and on Day 57 in the placebo group, suggesting that COVID-19 was rare and natural infection had not boosted the neutralizing antibody titers.…”

Section: Limitationmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

Cheng

Lien²,

Hsieh

et al. 2022

Preprint

View full text Add to dashboard Cite

Safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminium hydroxide, was assessed for people living with HIV (PWH). A total of 57 PWH of ≥ 20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received 2 doses of MVC-COV1901 28 days apart. No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5-4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. As a result, a third dose or booster doses of MVC-COV1901 may be appropriate for PWH.ClinicalTrials.gov registration: NCT04695652.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Limitationmentioning

confidence: 99%

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

Cheng

Lien²,

Hsieh

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…( Table 4 ). Despite the abovementioned studies, the numbers of PWH participating in clinical trials that evaluated COVID-19 vaccines is still very limited [ 41 ]. Weaker neutralization antibody responses to the Spike protein were demonstrated in this study, similar to the protein-based vaccine, NVX-CoV2373, studied in South Africa, ref.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, extrapolation to people with HIV with lower CD4 counts or without suppressed HIV viral loads is not suggested. Recent studies have reported PWH with CD4+ T cell counts less than 200 cells/mm 3 presented weaker immunologic responses [ 37 , 38 , 39 , 40 , 41 ]. Second, our study was initiated when SARS-CoV-2 was not endemic in Taiwan, and the low viral transmission rate made it difficult to ascertain the efficacy of the vaccine as an exploratory endpoint.…”

Section: Limitationmentioning

confidence: 99%

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

et al. 2022

View full text Add to dashboard Cite

Background: This study aimed to assess the safety and immunogenicity of MVC-COV1901, a recombinant COVID-19 protein vaccine, containing S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide, for people living with HIV (PWH). Methods: A total of 57 PWH of ≥20 years of age who are on stable antiretroviral therapy were compared with 882 HIV-negative participants. Participants received two doses of MVC-COV1901 28 days apart. Results: No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in PWH and comparators, respectively, 28 days after the second dose. After adjusting for sex, age, BMI category, and comorbidity, the adjusted GMT ratio of comparator/PWH was 3.2 (95% CI 2.5–4). A higher CD4/CD8 ratio was associated with a higher GMT (R = 0.27, p = 0.039). MVC-COV1901 has shown robust safety but elicited weaker immune responses in PWH. Conclusions: Further investigations may be needed to determine whether PWH require distinct immunization strategies with improved immunogenicity. The main study is registered at ClinicalTrials.gov (NCT04695652).

show abstract

“…[ 55 ] The Ad26.COV2.S adenovirus vector vaccine (Janssen/Johnson & Johnson COVID-19 vaccine) trial enrolled 467 participants, the largest number of PLWH with well-controlled disease enrolled to date (with viral suppression, CD4 + T cell count ≥300 cells/μL), with no significant difference in safety compared with HIV-negative individuals. [ 57 ] However, another study found an increased risk of breakthrough infection, with the highest increase (3.3%) observed for the Janssen/Johnson & Johnson COVID-19 vaccine. [ 50 ] Notably, there are important concerns regarding the potential use of adenoviral vector vaccines in PLWH.…”

Section: Overview Of Sars-cov-2 Vaccination In Plwhmentioning

confidence: 99%

Advances in Research on COVID-19 Vaccination for People Living with HIV

et al. 2022

View full text Add to dashboard Cite

Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data

Cited by 6 publications

References 67 publications

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

A retrospective study of the safety and immunogenicity of MVC-COV1901 vaccine for people living with HIV

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

Advances in Research on COVID-19 Vaccination for People Living with HIV

Contact Info

Product

Resources

About